| Purpose | AGM Date | Announcement Date |
|---|---|---|
| AGM | 21 Jul 2025 | 19 May 2025 |
| Convening of the 74th Annual General Meeting of the Company on Monday, July 21, 2025, through Video-Conferencing (VC) / Other Audio Visual Means (OAVM) in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India. Pursuant to Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we submit herewith notice of the 74th Annual General Meeting scheduled on Monday, July 21, 2025. (As per BSE Announcement Dated on 29/06/2025) Please find enclosed proceedings of the 74th Annual General Meeting of the Company held on Monday, July 21, 2025 at 3.00 P.M. IST. (As Per BSE Announcement Dated on: 21/07/2025) Pursuant to Regulation 44 of SEBI (LODR) Regulations, 2015, we submit herewith the consolidated scrutinizers report of the votes cast during electronic voting and electronic polling process conducted during the 74th Annual General Meeting of the Company held on Monday, July 21, 2025 at 3.00 P.M. IST. (As per BSE Announcement Dated on 22/07/2025) | ||
| AGM | 28 Aug 2024 | 9 Aug 2024 |
| AGM 28/08/2024 Proceedings of the 73rd Annual General Meeting of the Company held on Wednesday, August 28, 2024. (As per BSE Announcement Dated on 28/08/2024) Pursuant to Regulation 44 of SEBI (LODR) Regulations, 2015 please find enclosed herewith the scrutinizers report on remote e-voting and e-voting during the 73rd Annual General Meeting held on Wednesday, August 28, 2024. Kindly note that all resolutions contained in the Notice of the 73rd Annual General Meeting have been duly passed by the Members with requisite majority. (As per BSE Announcement Dated on 29/08/2024) | ||
Ativan is a common medication used predominantly for anxiety disorders, whereas Pacitane is used for Parkinson’s disease and other neurological conditions.
The agreement, which is discussed up to April and approved by Pfizer's Board of Directors, will be for five years, with discussions ending on 21 February 2025.
Revenue from operations decline marginally by 0.4% YoY at ₹538 crore, as against ₹540 crore in Q3 FY24
At the operating level, EBITDA increased by 60.2%, reaching ₹177.5 Crore in the first quarter of this fiscal year, compared to ₹110.8 Crore in the same quarter last year.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
